Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Next Previous
Trial Profile

International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Bortezomib (Primary) ; Crisantaspase (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Etoposide (Primary) ; Fludarabine (Primary) ; Ifosfamide (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Pegaspargase (Primary) ; Prednisolone (Primary) ; Prednisolone (Primary) ; Prednisone (Primary) ; Tioguanine (Primary) ; Vincristine (Primary) ; Vindesine (Primary)
  • Indications Acute biphenotypic leukaemia; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms AIEOP-BFM ALL 2017

Most Recent Events

  • 10 Dec 2024 Results analyzing the perceived QoL and the psychosocial risk in pediatric patients affected by ALL-B, recruited in the AIEOP-BFM-ALL-2017 protocol (intermediate/high risk) and treated, after randomisation, with standard chemiotherapy (Group 1) or blinatumomab immunotherapy (Group 2), presented at the 66th American Society of Hematology Annual Meeting and Exposition
  • 12 Dec 2023 Results (n=728) assessing toxicity profile of B-cell acute lymphoblastic leukemia patients with high-risk characteristics pending final outcome data, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
  • 12 Dec 2023 Results collecting samples from this study analyzing Immune Profiling , presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top